New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
16:10 EDTRCPTReceptos files to sell common stock, no amount given
Receptos intends to use the net proceeds received from this offering to fund continued development of its product candidate RPC1063 in ongoing clinical trials for relapsing multiple sclerosis and ulcerative colitis, development of its in-licensed product candidate RPC4046 in a clinical trial for eosinophilic esophagitis, other ongoing preclinical and research programs and for general corporate purposes including working capital. International, Inc. are acting as co-managers. Credit Suisse Securities, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Wedbush PacGrow Life Sciences and Nomura Securities
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
12:57 EDTRCPTOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTRCPTHigh option volume stocks
Subscribe for More Information
09:20 EDTRCPTOn The Fly: Pre-market Movers
Subscribe for More Information
08:47 EDTRCPTReceptos price target raised to $125 from $72 at BMO Capital
Subscribe for More Information
08:13 EDTRCPTReceptos price target raised to $112 from $77 at Leerink
Subscribe for More Information
07:08 EDTRCPTReceptos price target raised to $153 from $80 at Wedbush
Wedbush raised Recptos' price target to $153 following strong Ulcerative Colitis results.
October 27, 2014
18:26 EDTRCPTOn The Fly: After Hours Movers
Subscribe for More Information
16:08 EDTRCPTReceptos up 32.7% after RPC1063 Phase 2 trial met primary, secondary endpoints
16:07 EDTRCPTReceptos reports RPC1063 Phase 2 trial met primary, all secondary endpoints
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use